OBJECTIVE: To assess the role of electrolyte imbalance in cardiac arrhythmias associated with congestive heart failure. DESIGN:Serum magnesium and potassium levels, urine magnesium excretion and the incidence of ventricular arrhythmias were assessed throughout the study. The patients who displayed complex arrhythmias after the first week of hospital medication were randomized 2:1 to double-blind magnesium supplementation or placebo. SETTING: The study was carried out in one municipal hospital, providing primary care. SUBJECTS: A total of 588 consecutive patients were screened for eligibility (clinical heart failure >/=6 months; NYHA class II-IV; left ventricular ejection fraction </=40%; sinus rhythm; serum creatinine </=2 mg dL-1). A total of 78 patients entered and 68 patients completed the study. INTERVENTIONS: Intravenous administration of magnesium (magnesium sulphate 8 g in 250 mL of 5% glucose) or placebo (250 mL of 5% glucose) over 12 h. MAIN OUTCOME MEASURES: (i) Incidence of ventricular arrhythmias in patients with hypomagnesemia; (ii) effects of magnesium supplementation on ventricular arrhythmias. RESULTS: On admission, hypomagnesemia was found in 38% and excessive magnesium loss in 72% of patients. Serum magnesium levels were lower and urine magnesium excretion was greater in patients with complex ventricular arrhythmias, both on admission and after treatment for heart failure. Intravenous administration of magnesium caused a significant decrease in the number of ventricular ectopic beats (P < 0.0001), couplets (P < 0.003) and episodes of nonsustained ventricular tachycardia (P < 0.01). CONCLUSIONS:Hypomagnesemia, probably related to increased urine magnesium excretion, is an essential feature of heart failure associated with complex ventricular arrhythmias. These arrhythmias can be alleviated/abolished by magnesium supplementation.
RCT Entities:
OBJECTIVE: To assess the role of electrolyte imbalance in cardiac arrhythmias associated with congestive heart failure. DESIGN: Serum magnesium and potassium levels, urine magnesium excretion and the incidence of ventricular arrhythmias were assessed throughout the study. The patients who displayed complex arrhythmias after the first week of hospital medication were randomized 2:1 to double-blind magnesium supplementation or placebo. SETTING: The study was carried out in one municipal hospital, providing primary care. SUBJECTS: A total of 588 consecutive patients were screened for eligibility (clinical heart failure >/=6 months; NYHA class II-IV; left ventricular ejection fraction </=40%; sinus rhythm; serum creatinine </=2 mg dL-1). A total of 78 patients entered and 68 patients completed the study. INTERVENTIONS: Intravenous administration of magnesium (magnesium sulphate 8 g in 250 mL of 5% glucose) or placebo (250 mL of 5% glucose) over 12 h. MAIN OUTCOME MEASURES: (i) Incidence of ventricular arrhythmias in patients with hypomagnesemia; (ii) effects of magnesium supplementation on ventricular arrhythmias. RESULTS: On admission, hypomagnesemia was found in 38% and excessive magnesium loss in 72% of patients. Serum magnesium levels were lower and urine magnesium excretion was greater in patients with complex ventricular arrhythmias, both on admission and after treatment for heart failure. Intravenous administration of magnesium caused a significant decrease in the number of ventricular ectopic beats (P < 0.0001), couplets (P < 0.003) and episodes of nonsustained ventricular tachycardia (P < 0.01). CONCLUSIONS:Hypomagnesemia, probably related to increased urine magnesium excretion, is an essential feature of heart failure associated with complex ventricular arrhythmias. These arrhythmias can be alleviated/abolished by magnesium supplementation.
Authors: Stephanie E Chiuve; Ethan C Korngold; James L Januzzi; Mary Lou Gantzer; Christine M Albert Journal: Am J Clin Nutr Date: 2010-11-24 Impact factor: 7.045
Authors: Chris Adamopoulos; Bertram Pitt; Xuemei Sui; Thomas E Love; Faiez Zannad; Ali Ahmed Journal: Int J Cardiol Date: 2008-07-30 Impact factor: 4.164
Authors: N Cohen; D Almoznino-Sarafian; R Zaidenstein; I Alon; O Gorelik; M Shteinshnaider; S Chachashvily; Z Averbukh; A Golik; Z Chen-Levy; D Modai Journal: Heart Date: 2003-04 Impact factor: 5.994
Authors: Jason Li; Kathleen M Hovey; Christopher A Andrews; Abdullah Quddus; Matthew A Allison; Linda Van Horn; Lisa W Martin; Elena Salmoirago-Blotcher; Yiqing Song; JoAnn E Manson; Christine M Albert; Bing Lu; Charles B Eaton Journal: J Womens Health (Larchmt) Date: 2019-12-12 Impact factor: 2.681